CYC.AX news and market signals

Cyclopharm has reported record revenue for the first half of 2026, driven by the accelerating rollout of its Technegas technology in the United States. This performance indicates a potential shift in capital allocation toward specialized diagnostic imaging providers within the broader healthcare market.